Management
Meenu Chhabra, President and Chief Executive Officer
Meenu Chhabra joined Allozyne, Inc as President and Chief Executive Officer in October 2007. Prior to joining the Allozyne team, Ms. Chhabra was Vice President Business Development and Licensing for Novartis (Switzerland). Immediately prior to joining Novartis, Ms Chhabra served as the Chief Business Officer at BioXell SpA (Italy). Ms. Chhabra also has held management positions at NeurAxon, Inc. and Fresenius Kabi AG, as well as sales and marketing roles at Parke Davis/Warner Lambert, Inc. and Bristol-Myers Squibb, Inc. Ms. Chhabra obtained her Hons B.Sc. degree from the University of Toronto in Pharmacology and her Masters Business Administration from the Schulich School of Business at York University.
Kenneth Grabstein, Ph.D., Chief Scientific Officer
Kenneth Grabstein joined Allozyne, Inc. as Chief Scientific Officer in October of 2005. Prior to joining the Allozyne team, Dr. Grabstein was at Immunex Inc, where he spent 12 years in R&D leading the discovery and characterization of cytokines and other protein immuno-modulators. He went on to co-found Corixa Inc and led a research team of 100 scientists engaged in the discovery and development of immuno-therapeutics. He has published over 100 articles in peer-reviewed scientific journals and is an inventor on over 20 issued patents. Dr. Grabstein has Affiliate Faculty positions at the University of Washington, and Roswell Park Cancer Institute. Kenneth Grabstein, Ph.D., received his Ph.D. in Immunology from U.C. Berkeley in 1982.
Hans van Houte, Vice President, Finance and Administration
Hans van Houte joined Allozyne from Trubion Pharmaceuticals, Inc. in January 2008 as Vice President, Finance and Administration. At Trubion, he was Vice President, Finance and Administration from 2003 to 2008. His duties included directing the finance, accounting and business operations of the Company from its inception to post initial public offering. Before joining Trubion, Mr. van Houte was Vice President, Finance at Ostex International and prior to that he was the Controller and Assistant Treasurer at Vertex Pharmaceuticals, Inc. In these positions he directed the finance and accounting functions and oversight of all SEC-related activities. Mr. van Houte received his B.S. from Babson College.
Jie Liu D’Elia, Vice President, Business Development and Licensing
Jie Liu D’Elia joined Allozyne as Vice President, Business Development and Licensing in June 2008. Prior to joining Allozyne, Dr. D’Elia served as Director, Business Development and New Product Planning, at AstraZeneca China from 2006 to 2008. She previously served as Senior Manager, Business Development at Nastech Pharmaceutical, a Consultant for Boston Consulting Group, and as a Senior Scientist at Baxter Healthcare. She has published 19 scientific research articles and holds 3 US patents. Dr. D’Elia received her Ph.D. in Pharmacy from The University of Texas at Austin, her Masters Business Administration from Columbia University and her Bachelor’s degrees in Chemistry and English from Tianjin University.
Keith Munson, Senior Director of Program Management
Keith Munson joined Allozyne, Inc., as Senior Director of Program Management in February 2008. Prior to joining the Allozyne team, Mr. Munson was Director of Therapeutic Development at Targeted Genetics Corporation where he was responsible for project management, preclinical and bioanalytics. Staring in 1996 at Targeted Genetics, he also served in a variety of scientific positions in research and preclinical, including as senior manager of toxicology since 2003. Mr. Munson received his B.A. in Chemistry and Biology from Whitman College and his Masters of Business Administration from the University of Washington.
